Dalriada Drug Discovery Inc.
$500,000.00
National Research Council Canada | Conseil national de recherches Canada
Industrial Research Assistance Program – Contributions to Firms
FY 2025-2026
Canada
E!7296 COVANEXT: Unlocking druggability of disordered proteins Co-International partner: Nuage Therapeutics SL, Spain To advance the development of NT-A, a first-in-class covalent therapeutic for...